HLVX
Sign in
Hillevax Inc
Save
92.64M
Market cap
–
Current P/E
–
Forward P/E
About
Health care
Sector
Biotechnology
Industry
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
Similar securities
Based on sector and market capitalization
Report issue